Price T Rowe Associates Inc. MD Has $8.94 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Price T Rowe Associates Inc. MD lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 264.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 297,101 shares of the biopharmaceutical company's stock after buying an additional 215,601 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.19% of TG Therapeutics worth $8,944,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Arizona State Retirement System boosted its position in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after acquiring an additional 364 shares during the last quarter. Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after buying an additional 463 shares during the period. Brookstone Capital Management boosted its position in TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after buying an additional 624 shares during the last quarter. Finally, Daymark Wealth Partners LLC raised its stake in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after buying an additional 689 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TGTX has been the subject of a number of recent research reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Stock Down 0.0 %

Shares of TGTX traded down $0.01 during midday trading on Friday, hitting $33.85. The company had a trading volume of 880,313 shares, compared to its average volume of 3,012,489. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market cap of $5.37 billion, a price-to-earnings ratio of -338.47 and a beta of 2.21. The company's 50 day moving average price is $38.94 and its 200 day moving average price is $33.49.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same period last year, the firm posted ($0.07) EPS. The business's quarterly revenue was up 90.4% on a year-over-year basis. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.